Literature DB >> 24081749

[Current diagnostic requirements in chronic myeloid leukemia].

Thomas Lion1, Gerald Webersinke, Ulrike Kastner, Christoph Seger, Gerlinde Mitterbauer-Hohendanner, Günther Gastl.   

Abstract

In patients with chronic myeloid leukemia, high-quality diagnostics is of paramount importance for the surveillance of treatment efficacy. The availability of new tyrosine kinase inhibitors providing more rapid and deeper responses requires the employment of standardized and highly sensitive diagnostic methods to ensure optimal monitoring of the patients. This review presents the current international diagnostic standards and the certified laboratories in Austria.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24081749     DOI： 10.1007/s10354-013-0239-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  84 in total

1.  Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Authors:  Claudia Haferlach; Harald Rieder; Debra M Lillington; Nicole Dastugue; Anne Hagemeijer; Jochen Harbott; Stephan Stilgenbauer; Sakari Knuutila; Bertil Johansson; Christa Fonatsch
Journal:  Genes Chromosomes Cancer       Date:  2007-05       Impact factor: 5.006

Review 2.  The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.

Authors:  Jennifer F T Teng; Vincent H Mabasa; Mary H H Ensom
Journal:  Ther Drug Monit       Date:  2012-02       Impact factor: 3.681

3.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Authors:  A Hochhaus; S G O'Brien; F Guilhot; B J Druker; S Branford; L Foroni; J M Goldman; M C Müller; J P Radich; M Rudoltz; M Mone; I Gathmann; T P Hughes; R A Larson
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528

4.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

5.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

Authors:  Susan Branford; Linda Fletcher; Nicholas C P Cross; Martin C Müller; Andreas Hochhaus; Dong-Wook Kim; Jerald P Radich; Giuseppe Saglio; Fabrizio Pane; Suzanne Kamel-Reid; Y Lynn Wang; Richard D Press; Kevin Lynch; Zbigniew Rudzki; John M Goldman; Timothy Hughes
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

Review 6.  Chronic myeloid leukaemia.

Authors:  Rüdiger Hehlmann; Andreas Hochhaus; Michele Baccarani
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

7.  Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.

Authors:  JoAnn C Kelly; Nasrin Shahbazi; Jay Scheerle; Jennifer Jahn; Stephany Suchen; Nicole C Christacos; Philip N Mowrey; Mary H Witt; Alden Hostetter; Aurelia M Meloni-Ehrig
Journal:  Cancer Genet Cytogenet       Date:  2009-07

8.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

9.  Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Authors:  Dragana Milojkovic; Jane F Apperley; Gareth Gerrard; Amr R Ibrahim; Richard Szydlo; Marco Bua; Alistair Reid; Katayoun Rezvani; Letizia Foroni; John Goldman; David Marin
Journal:  Blood       Date:  2011-12-14       Impact factor: 22.113

10.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.